Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study
Oncology Research · 2026 · 34 (5) · 1-10
DOI: 10.32604/or.2026.074095 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Oncology Research, 2026. Verfasst von Laura Duzzi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: C-Reactive Protein, Immune Checkpoint Inhibitors, Neoplasms, Nervous System Diseases. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hannover Medical School, Hannover, Germany.
- Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Department of Pneumology, Hannover Medical School, Hannover, Germany.
- Department of Gastroenterology, Hannover Medical School, Hannover, Germany.
- Skin-Cancer-Center, Department of Dermatology, Allergology, and Venereology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, Germany.
- Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany.
Zitieren
APA
Duzzi, L., Möhn, N., Narten, E., Thomas, J., Mahjoub, S., Grote-Levi, L., Jendretzky, K., Nay, S., Konen, F., Wiegmann, J., Beutel, G., Fröhlich, T., Bollmann, B. A., Wirth, T., von Wasielewski, I., Heidel, F. H., Gutzmer, R., Skripuletz, T., Ivanyi, P., & ICOG (Immune Cooperative Oncology Group)-Investigators (2026). Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study. Oncology Research, 34(5), 1-10. https://doi.org/10.32604/or.2026.074095
Vancouver
Duzzi L, Möhn N, Narten E, Thomas J, Mahjoub S, Grote-Levi L, et al. Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study. Oncology Research. 2026;34(5):1-10. doi:10.32604/or.2026.074095
BibTeX
@article{Duzzi2026,
author = {Duzzi, Laura and Möhn, Nora and Narten, Emily and Thomas, Janin and Mahjoub, Susann and Grote-Levi, Lea and Jendretzky, Konstantin and Nay, Sandra and Konen, Felix and Wiegmann, Jonas and Beutel, Gernot and Fröhlich, Tabea and Bollmann, Benjamin-Alexander and Wirth, Thomas and von Wasielewski, Imke and Heidel, Florian H and Gutzmer, Ralf and Skripuletz, Thomas and Ivanyi, Philipp and ICOG (Immune Cooperative Oncology Group)-Investigators, ICOG (Immune Cooperative Oncology Group)-Investigators},
title = {Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort Study},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {5},
pages = {1--10},
doi = {10.32604/or.2026.074095}
}
EUVIMED